You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,089,570

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,089,570

Title:	Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Abstract:	This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific regimens of chemotherapeutic and/or targeted drugs designed to overcome the genomic resistance raised to prior therapy.
Inventor(s):	Karmali; Rashida A (Brooklyn, NY)
Assignee:	TACTICAL THERAPEUTICS INC (New York, NY)
Application Number:	13/986,103
Patent Claims:	1. A pharmaceutical composition of an effective amount of carboxyamidotriazole orotate that prevents or overcomes acquired resistance to chemotherapeutic drugs and targeted drugs due to by gene amplification or mutation, wherein the effective amount of the composition is in the range 50 mg/m.sup.2 to 1500 mg/m.sup.2 based on the patient's body surface. 2. The pharmaceutical composition according to claim 1, further comprising one or more chemotherapeutic drugs of choice used in a regimen designed for overcoming acquired drug resistance and treating a cancer selected from the group consisting of breast, colon, head and neck, malignant glioma, glioblastoma, lung, non-small cell lung, melanoma, testicular, gastrointestinal stromal tumor, ovarian, prostate and chronic myeloid leukemia. 3. The pharmaceutical composition according to claim 1, further comprising one or more targeted drugs of choice used in a regimen designed for overcoming acquired drag resistance and treating a cancer selected from the group consisting of breast, colon, head and neck, malignant glioma, glioblastoma, lung, non-small cell lung, melanoma, testicular, gastrointestinal stromal tumor, ovarian, prostate and chronic myeloid leukemia. 4. The pharmaceutical composition according to claim 1, further comprising a chemotherapeutic drug of choice used in a regimen designed for treating a cancer and a targeted drug of choice used in a regimen designed for overcoming acquired drug resistance and treating a cancer selected from the group consisting of breast, colon, head and neck, malignant glioma, glioblastoma, lung, non-small cell lung, melanoma, testicular, gastrointestinal stromal tumor, ovarian, prostate and chronic myeloid leukemia. 5. The pharmaceutical composition according to claim 2 wherein the chemotherapeutic is paclitaxel. 6. The pharmaceutical composition of 3 wherein the targeted is erlotinib. 7. The pharmaceutical composition according to claim 2 wherein the chemotherapeutic drug is carboplatin. 8. The pharmaceutical composition according to claim 2 wherein the chemotherapeutic drug is premetrexed. 9. The pharmaceutical composition according to claim 2 wherein the chemotherapeutic drug is docetaxel. 10. The pharmaceutical composition according to claim 2 wherein the chemotherapeutic drug is lomustine. 11. The pharmaceutical composition according to claim 2 wherein the chemotherapeutic drug is gemeitabine. 12. The pharmaceutical composition of claim 3 wherein the targeted drug is cetuximab. 13. The pharmaceutical composition of claim 3 wherein the targeted drug is panitumumab. 14. The pharmaceutical composition of claim 3 wherein the targeted drug is imatinib. 15. The pharmaceutical composition of claim 3 wherein the targeted drug is trastuzumab. 16. The pharmaceutical composition of claim 3 wherein the targeted drug is bevacizumab. 17. The pharmaceutical composition of claim 3 wherein the targeted drug is vemurafenib. 18. The pharmaceutical composition of claim 3 wherein the targeted drug is ipilimumab. 19. The pharmaceutical composition of claim 3 wherein the targeted drug is tarceva.

Details for Patent 9,089,570

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2039-02-26
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2039-02-26
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.